The Cempra Inc. (CEMP) Cut to Market Perform at Cowen and Company

The Cempra Inc. (CEMP) Cut to Market Perform at Cowen and Company

Cempra Inc. (NASDAQ:CEMP) was downgraded by research analysts at Cowen and Company from an “outperform” rating to a “market perform” rating in a research note issued on Monday. Other equities research analysts have also recently issued research reports about the company. Zacks Investment Research upgraded Cempra from a “hold” rating to a “buy” rating and set a $25.00 price objective on the stock in a research note on Thursday, August 4th. Needham & Company LLC reiterated a “buy” rating and set a $48.00 price objective on shares of Cempra in…

The Myovant Sciences Ltd (MYOV) Receives New Coverage from Analysts at Barclays PLC

The Myovant Sciences Ltd (MYOV) Receives New Coverage from Analysts at Barclays PLC

Analysts at Barclays PLC began coverage on shares of Myovant Sciences Ltd (NASDAQ:MYOV) in a note issued to investors on Monday, The Fly reports. The firm set an “overweight” rating on the stock. Separately, Robert W. Baird began coverage on Myovant Sciences in a research note on Monday. They set an “outperform” rating and a $20.00 price objective for the company. Shares of Myovant Sciences (NASDAQ:MYOV) opened at 11.25 on Monday. The firm’s 50-day moving average is $11.46 and its 200-day moving average is $11.46. The company’s market cap is…

The Aon PLC (AON) Upgrade by Keefe, Bruyette & Woods to Outperform

The Aon PLC (AON) Upgrade by Keefe, Bruyette & Woods to Outperform

Aon PLC (NYSE:AON) was upgraded by research analysts at Keefe, Bruyette & Woods from a “market perform” rating to an “outperform” rating in a note issued to investors on Monday, The Fly reports. AON has been the subject of several other reports. Credit Suisse Group AG restated a “sell” rating on shares of Aon PLC in a research note on Monday, August 1st. Zacks Investment Research upgraded Aon PLC from a “sell” rating to a “hold” rating in a research note on Wednesday, August 31st. Citigroup Inc. boosted their price…

The Myovant Sciences Ltd (MYOV) Research Coverage Started at JMP Securities

The Myovant Sciences Ltd (MYOV) Research Coverage Started at JMP Securities

Research analysts at JMP Securities started coverage on shares of Myovant Sciences Ltd (NASDAQ:MYOV) in a research report issued on Monday, The Fly reports. The brokerage set an “outperform” rating on the stock. Several other analysts also recently commented on MYOV. Barclays PLC began coverage on shares of Myovant Sciences in a research report on Monday. They issued an “overweight” rating for the company. Robert W. Baird began coverage on shares of Myovant Sciences in a research report on Monday. They issued an “outperform” rating and a $20.00 target price…

The Canadian Solar Inc. (CSIQ) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS

The Canadian Solar Inc. (CSIQ) Releases Quarterly  Earnings Results, Beats Estimates By $0.03 EPS

Canadian Solar Inc. (NASDAQ:CSIQ) announced its earnings results on Monday. The company reported $0.27 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.24 by $0.03. The company had revenue of $657.30 million for the quarter, compared to analysts’ expectations of $685.28 million. Canadian Solar had a return on equity of 19.73% and a net margin of 4.45%. During the same quarter in the previous year, the firm earned $0.53 earnings per share. Shares of Canadian Solar (NASDAQ:CSIQ) opened at 11.70 on Monday. The company…

The Insider Buying: Cadiz Inc. (CDZI) Director Buys $134,100.00 in Stock

The Insider Buying: Cadiz Inc. (CDZI) Director Buys $134,100.00 in Stock

Cadiz Inc. (NASDAQ:CDZI) Director Winston H. Hickox acquired 15,000 shares of the firm’s stock in a transaction on Tuesday, November 15th. The stock was purchased at an average cost of $8.94 per share, with a total value of $134,100.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Winston H. Hickox also recently made the following trade(s): On Thursday, November 17th, Winston H. Hickox acquired 5,000 shares of Cadiz stock. The stock was purchased at an average cost of $9.13 per share,…

The Insider Selling: Trimble Navigation Ltd. (TRMB) CFO Sold $143,900.00 in Stock

The Insider Selling: Trimble Navigation Ltd. (TRMB) CFO Sold $143,900.00 in Stock

Trimble Navigation Ltd. (NASDAQ:TRMB) CFO Robert G. Painter sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, November 15th. The stock was sold at an average price of $28.78, for a total transaction of $143,900.00. Following the completion of the sale, the chief financial officer now directly owns 14,323 shares of the company’s stock, valued at approximately $412,215.94. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Shares of Trimble Navigation Ltd. (NASDAQ:TRMB) opened at 27.51…

The Steris Corp. (STE) VP Sold $147,400.00 in Stock

The Steris Corp. (STE) VP Sold $147,400.00 in Stock

Steris Corp. (NYSE:STE) VP John Adam Zangerle sold 2,200 shares of the firm’s stock in a transaction dated Tuesday, November 15th. The shares were sold at an average price of $67.00, for a total value of $147,400.00. Following the completion of the transaction, the vice president now owns 26,166 shares in the company, valued at approximately $1,753,122. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Steris Corp. (NYSE:STE) opened at 65.94 on Monday. The company has a…

The 3,800 Shares of Forrester Research Inc. (FORR) Stock are sold by Gretchen Teichgraeber

The 3,800 Shares of Forrester Research Inc. (FORR) Stock are sold by Gretchen Teichgraeber

Forrester Research Inc. (NASDAQ:FORR) Director Gretchen Teichgraeber sold 3,800 shares of the business’s stock in a transaction on Thursday, November 17th. The shares were sold at an average price of $39.79, for a total transaction of $151,202.00. Following the transaction, the director now directly owns 7,748 shares of the company’s stock, valued at approximately $308,292.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Shares of Forrester Research Inc. (NASDAQ:FORR) opened at 40.85 on Monday. The company has…

The 4,000 Shares of Cooper Tire & Rubber Co. (CTB) Stock are sold by John J. Holland

The 4,000 Shares of Cooper Tire & Rubber Co. (CTB) Stock are sold by John J. Holland

Cooper Tire & Rubber Co. (NYSE:CTB) Director John J. Holland sold 4,000 shares of the business’s stock in a transaction on Wednesday, November 16th. The shares were sold at an average price of $37.86, for a total transaction of $151,440.00. Following the sale, the director now directly owns 5,913 shares of the company’s stock, valued at approximately $223,866.18. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Cooper Tire & Rubber Co. (NYSE:CTB) opened at 38.45 on Monday. The stock has…

The 3,772 Shares of WSFS Financial Corp. (WSFS) Stock are sold by Paul D. Geraghty

The 3,772 Shares of WSFS Financial Corp. (WSFS) Stock are sold by Paul D. Geraghty

WSFS Financial Corp. (NASDAQ:WSFS) EVP Paul D. Geraghty sold 3,772 shares of the company’s stock in a transaction on Wednesday, November 16th. The stock was sold at an average price of $40.53, for a total transaction of $152,879.16. Following the transaction, the executive vice president now owns 31,699 shares of the company’s stock, valued at approximately $1,284,760.47. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. WSFS Financial Corp. (NASDAQ:WSFS) opened at 41.05 on Monday. The stock has a market cap of $1.29…

The 347,609 Shares of A.M. Castle & Co. (CAS) Stock are sold by Stone House Capital Management

The 347,609 Shares of A.M. Castle & Co. (CAS) Stock are sold by Stone House Capital Management

A.M. Castle & Co. (NYSE:CAS) major shareholder Stone House Capital Management sold 347,609 shares of A.M. Castle & Co. stock in a transaction dated Thursday, November 17th. The shares were sold at an average price of $0.47, for a total transaction of $163,376.23. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC. Stone House Capital Management also recently made the…

The Lakeland Bancorp Inc. (LBAI) Director Sold $165,000.00 in Stock

The Lakeland Bancorp Inc. (LBAI) Director Sold $165,000.00 in Stock

Lakeland Bancorp Inc. (NASDAQ:LBAI) Director Edward B. Deutsch sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 15th. The shares were sold at an average price of $16.50, for a total value of $165,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Edward B. Deutsch also recently made the following trade(s): On Friday, November 18th, Edward B. Deutsch sold 19,010 shares of Lakeland Bancorp stock. The stock was sold at an…

The Stage Stores Inc. Forecasted to Earn Q4 2017 Earnings of $0.81 Per Share (SSI)

The Stage Stores Inc. Forecasted to Earn Q4 2017 Earnings of $0.81 Per Share (SSI)

Stage Stores Inc. (NYSE:SSI) – Analysts at B. Riley decreased their Q4 2017 earnings per share (EPS) estimates for Stage Stores in a research report issued on Friday. B. Riley analyst J. Van. Sinderen now anticipates that the firm will post earnings per share of $0.81 for the quarter, down from their prior estimate of $1.01. B. Riley currently has a “Neutral” rating and a $3.50 target price on the stock. B. Riley also issued estimates for Stage Stores’ Q4 2018 earnings at $0.89 EPS. Stage Stores (NYSE:SSI) last issued…

The Stryker Corp. (SYK) Upgrade to “Buy” by The Zacks Investment Research

The Stryker Corp. (SYK) Upgrade to “Buy” by The  Zacks Investment Research

Zacks Investment Research upgraded shares of Stryker Corp. (NYSE:SYK) from a hold rating to a buy rating in a report released on Tuesday morning. Zacks Investment Research currently has $119.00 target price on the medical technology company’s stock. According to Zacks, “Stryker ended the third quarter of 2016 on a solid note, squarely beating the Zacks Consensus Estimate. We believe the company’s innovative product pipeline will be a key catalyst in the near term. Additionally, growing adoption of MAKO will drive sales in the orthopedic and reconstructive surgery market. The…

The BTIG Research Downgraded Teva Pharmaceutical Industries Ltd. (TEVA) to Neutral

The BTIG Research Downgraded Teva Pharmaceutical Industries Ltd. (TEVA) to Neutral

BTIG Research downgraded shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) from a buy rating to a neutral rating in a research report sent to investors on Wednesday. A number of other analysts have also commented on the stock. Jefferies Group lowered shares of Teva Pharmaceutical Industries from a buy rating to a hold rating and cut their price objective for the stock from $69.00 to $40.00 in a research report on Wednesday, November 16th. Mizuho dropped their price target on shares of Teva Pharmaceutical Industries from $45.00 to $40.00 and…

The Cidara The rapeutics Inc. (CDTX) Upgrade to Buy by The Zacks Investment Research

The Cidara The rapeutics Inc. (CDTX) Upgrade to Buy by The  Zacks Investment Research

Zacks Investment Research upgraded shares of Cidara Therapeutics Inc. (NASDAQ:CDTX) from a hold rating to a buy rating in a research note issued to investors on Tuesday. Zacks Investment Research currently has $13.00 price target on the biotechnology company’s stock. According to Zacks, “Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical and C001 which are in different clinical trial. The company developed its product using Cloudbreak(TM)…

The Capital City Bank Group (CCBG) Raised to “Hold” at The Zacks Investment Research

The Capital City Bank Group (CCBG) Raised to “Hold” at The  Zacks Investment Research

Zacks Investment Research upgraded shares of Capital City Bank Group (NASDAQ:CCBG) from a sell rating to a hold rating in a research note issued to investors on Wednesday. According to Zacks, “Capital City Bank Group, Inc. is a financial holding company with banking subsidiaries and numerous indirect subsidiaries. The Banks are full service banks, engaged in the commercial and retail banking business, including accepting demand, savings and time deposits; extending credit; originating residential mortgage loans; and providing data processing services, asset management services, trust services, retail brokerage services and a…

The Cracker Barrel Old Country Store Inc. (CBRL) Rating Increased to Hold at The Zacks Investment Research

The Cracker Barrel Old Country Store Inc. (CBRL) Rating Increased to Hold at The  Zacks Investment Research

Zacks Investment Research upgraded shares of Cracker Barrel Old Country Store Inc. (NASDAQ:CBRL) from a sell rating to a hold rating in a research note released on Tuesday morning. According to Zacks, “Cracker Barrel Old Country Store, Inc., formerly CBRL Group, Inc., is principally engaged in the operation and development of the Cracker Barrel Old Country Store restaurant and retail concept. The format of Cracker Barrel stores consists of a rustic, old country-store design with a separate retail area offering a variety of decorative and functional items featuring rocking chairs,…

The CymaBay The rapeutics Inc. (CBAY) Decreased to Hold at The Zacks Investment Research

The CymaBay The rapeutics Inc. (CBAY) Decreased to Hold at The  Zacks Investment Research

Zacks Investment Research lowered shares of CymaBay Therapeutics Inc. (NASDAQ:CBAY) from a buy rating to a hold rating in a research note issued to investors on Tuesday. According to Zacks, “CymaBay Therapeutics Inc. is a biopharmaceutical company. It is focused on the development and commercialization of proprietary new medicines for important human diseases. The Company’s lead product candidate, arhalofenate, is being developed for the treatment of gout. CymaBay Therapeutics Inc. is based in Newark, California. “ CymaBay Therapeutics (NASDAQ:CBAY) opened at 2.08 on Tuesday. CymaBay Therapeutics has a 12 month…